Agessandro Abrahao

Dr. Agessandro Abrahao

Co-Applicant

Assistant Professor of Medicine (Neurology) at  University of Toronto | Staff Neurologist at Sunnybrook Health Sciences Centre

Associate Scientist at Sunnybrook Health Sciences Centre


NMD4C Involvement: Pillar 2: Clinical Research, Pillar 3: Clinical Practice Research

Email Agessandro

Research Interests: ALS, clinical trials, drug development, Neurophysiological biomarkers, MR-guided focused ultrasound for neurological diseases

Academic web profile
Google Scholar profile
ResearchGate profile

Biography

Agessandro Abrahao, MD, is an academic neurologist with MSc degree in Neuroscience from the Federal University of Sao Paulo, Brazil and in Clinical Epidemiology from the Institute of Health Policy, Management and Evaluation, University of Toronto. He completed an advanced fellowship training in ALS/ Neuromuscular Diseases at Sunnybrook Health Sciences Centre – University of Toronto and is certified in EMG techniques by the Canadian Society of Clinical Neurophysiologists. Agessandro also served as the inaugural Sunnybrook Neuromodulation/Focused Ultrasound Fellow. 

Agessandro’s research aims to accelerate the drug development and clinical trials for ALS. His research interests also include clinical trials and epidemiological studies in ALS and other neuromuscular disorders. He is also interested in the development of biomarkers for motor neuron function using transcranial magnetic stimulation and motor unit count techniques. 


Recent Publications

Parks, ASE, Conn, LG, Aria, B, Paul, MR, Li, A, Abrahao, A et al.. Qualitative dyadic analysis in care partnership research: a scoping review. BMC Med Res Methodol. 2025. PMID:41372818

Suthananthan, I, Scantlebury, N, Boudah, A, Rohringer, C, Schwartz, ML, Lipsman, N et al.. Access to MRgFUS Thalamotomy for Essential Tremor in Ontario: Geographic & Socioeconomic Referral Patterns. Can J Neurol Sci. 2025. 1-10 PMID:41367133

Saunders, N, Magnussen, C, Kang, H, Blais, M, Bhinder, H, Pfeffer, G et al.. Comprehensive analysis platform to understand, remedy, and eliminate amyotrophic lateral sclerosis (CAPTURE ALS): Study protocol for a Canadian multicenter, multimodal, longitudinal observational study. PLoS One. 2025.20 (12)e0332430 PMID:41343582

Woodworth, GF, Anastasiadis, P, Ozair, A, Chabros, J, Bettegowda, C, Chen, C et al.. Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2025.26 (12)1651-1664 PMID:41308679

Sit, V, Kumar, R, Scantlebury, N, Boshmaf, SZ, Sivadas, S, Rohringer, CR et al.. Non-motor outcomes following focused ultrasound thalamotomy for tremor. Parkinsonism Relat Disord. 2025.142 108106 PMID:41202510

Baumeister, TR, Westeneng, HJ, van den Berg, L, Canadian ALS Neuroimaging Consortium (CALSNIC), Kalra, S, Iturria-Medina, Y et al.. Multimodal Neuroimaging-Guided Stratification in Amyotrophic Lateral Sclerosis Reveals Three Disease Subtypes: A Multi-Cohort Analysis. Hum Brain Mapp. 2025.46 (14)e70341 PMID:40990258

Bonares, MJ, Shapiro, J, Vijayanathan, V, Abrahao, A, Zinman, L, Lau, C et al.. Goal-Concordant Care in People With Amyotrophic Lateral Sclerosis Receiving Palliative Care. J Pain Symptom Manage. 2025.70 (6)679-690 PMID:40935268

Abrahao, A, Da Silva, P, Ciepielewska, M, Zinman, L. Real-world safety and tolerability of intravenous edaravone in patients with amyotrophic lateral sclerosis. Neurodegener Dis Manag. 2025.15 (6)305-312 PMID:40878665

Fanella, G, Bostock, H, Samusyte, G, Jacobsen, AB, Howells, J, Cengiz, B et al.. Short-interval intracortical inhibition (SICI): effect of target tracking on variability of responses for 1 mV and 200µV test-alone targets. Neurophysiol Clin. 2025.55 (5)103091 PMID:40639034

De Schlichting, E, Meng, Y, Huang, Y, Jones, RM, Hynynen, K, Hamani, C et al.. Magnetic resonance-guided ultrasound thalamotomy for essential tremor: a review. Expert Rev Med Devices. 2025.22 (9)989-997 PMID:40621904

See more on PubMed